CLAIMS

1. A method of diagnosing or monitoring the progression of a neurodegenerative tauopathy in a subject**,** the method comprising

(a) measuring the level of pathologically modified or aggregated tau in a sample from the subject to be diagnosed with an anti-tau antibody or tau-binding fragment thereof, comprising a heavy chain variable domain (VH) wherein: VH complementarity determining region (CDR)1 comprises the amino acids set forth in SEQ ID NO:151, VH CDR2 comprises the amino acids set forth in SEQ ID NO:152, and VH CDR3 comprises the amino acids set forth in SEQ ID NO:153; and

(b) comparing the level of modified or aggregated tau to a reference standard that indicates the level of the pathologically modified or aggregated tau in one or more control subjects,

wherein a difference or similarity between the level of pathologically modified or aggregated tau and the reference standard indicates that the subject has a neurodegenerative tauopathy.